News

Public · Published

Morgan Stanley maintains Cerebras Systems at Overweight, lowers price target to $178 from $279

Morgan Stanley kept its Overweight rating on Cerebras Systems but cut its price target to $178 from $279, a 36.2% decrease. The new target implies 98.5% upside from the November 6 closing price of $89.68.

Published:

Updated:

What happened

Morgan Stanley kept its Overweight rating on Cerebras Systems but cut its price target to $178 from $279, a 36.2% decrease. The new target implies 98.5% upside from the November 6 closing price of $89.68.

Confirmed

Global impact / market context

The lower target signals Morgan Stanley now sees less potential value for Cerebras than before, even while keeping its positive rating. Investors may reassess expectations for the stock, but the article gives no explanation for the cut or evidence of a change in Cerebras’s business results.

Analyst inference

Cerebras analyst targets range from $175 to $250 across three recent notes, while Morgan Stanley set $178. These differing estimates can influence investor expectations about the company’s share value, but the article reports no resulting changes to company revenue, costs, or capital spending.

Analyst inference

What to watch

  1. Check for a later Morgan Stanley rating or target revision; another cut or a reversal could change how investors interpret its view of Cerebras. Analyst inference
  2. Compare future analyst targets with the cited $175–$250 range to see whether estimates cluster or remain widely spread, indicating differing expectations for the stock. Analyst inference
  3. Look for company results or business updates that could explain the reduced target; none are identified in the supplied article. Analyst inference

Evidence

  • Original source link unavailable